Wells Fargo
KRON

Wells Fargo’s Kronos Bio KRON Stock Holding History

Wells Fargo’s Portfolio KRON Stock Details KRON Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q2 		– Sell
-347
Closed -$451 – 7202
2024
Q1 		$451 Buy
347
+6
+2% +$7 ﹤0.01% 6300
2023
Q4 		$426 Buy
341
+18
+6% +$20 ﹤0.01% 6421
2023
Q3 		$420 Sell
323
-4,997
-94% -$8.07K ﹤0.01% 6402
2023
Q2 		$9.15K Sell
5,320
-6,935
-57% -$11K ﹤0.01% 5929
2023
Q1 		$17.9K Buy
+12,255
New +$23.5K ﹤0.01% 5678
2022
Q4 		– Sell
-124
Closed – – 7602
2022
Q3 		$0 Sell
124
-397
-76% -$1.79K ﹤0.01% 7031
2022
Q2 		$2K Sell
521
-2,718
-84% -$12.3K ﹤0.01% 6336
2022
Q1 		$24K Sell
3,239
-13,395
-81% -$114K ﹤0.01% 5948
2021
Q4 		$226K Buy
16,634
+12,246
+279% +$192K ﹤0.01% 5199
2021
Q3 		$92K Buy
4,388
+4,269
+3,587% +$91.7K ﹤0.01% 5419
2021
Q2 		$3K Sell
119
-4,523
-97% -$115K ﹤0.01% 6463
2021
Q1 		$136K Sell
4,642
-2,935
-39% -$86K ﹤0.01% 5338
2020
Q4 		$226K Buy
+7,577
New +$238K ﹤0.01% 5021

Other funds holding KRON

VVA
Vida Ventures Advisors Boston, Massachusetts $29.4M AUM 93.58% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
PCIG
Partners Capital Investment Group Boston, Massachusetts $2.83B AUM 20.31% 1-Year Est. Return
AI
Alphabet Inc Mountain View, California $99.1B AUM 124.46% 1-Year Est. Return
WCM
Wildcat Capital Management New York $229M AUM 132.65% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return
Mariner
Mariner Overland Park, Kansas $95.2B AUM 32.92% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
AG
Artal Group Luxembourg $931M AUM 41.63% 1-Year Est. Return

Wells Fargo's KRON Position: Q2 2024 in Review

Wells Fargo sold out of Kronos Bio (KRON) in Q2 2024, closing a stake of 347 shares — an estimated $451 sold.

Wells Fargo first reported a position in KRON in Q4 2020 and held it in 13 quarters. The position peaked at $226K in Q4 2021. 56 funds tracked by Wall St. Rank hold KRON as of Q2 2024.

  • Wells Fargo reported no remaining Kronos Bio position as of Q2 2024 after selling out during the quarter.
  • Wells Fargo sold 347 Kronos Bio shares in Q2 2024, an estimated $451.
  • Wells Fargo first reported a position in Kronos Bio in Q4 2020 and held it in 13 quarters.
  • Wells Fargo's Kronos Bio position peaked at $226K in Q4 2021.
  • 56 funds tracked by Wall St. Rank held Kronos Bio as of Q2 2024.

Based on Wells Fargo's 13F filing for Q2 2024, filed 13 Aug 2024.